Panic Attacks: Drugs That Cause or Treat Them

What Exactly Happens During a Panic Attack

A panic attack is a discrete surge of intense fear that peaks within minutes and produces at least four physical or cognitive symptoms: palpitations, shortness of breath, chest pain, dizziness, derealization, or fear of dying. The DSM-5 distinguishes expected attacks (triggered by a known stressor) from unexpected attacks, which arise without an obvious cue. Unexpected, recurrent attacks accompanied by at least one month of persistent worry about future attacks or maladaptive behavioral change meet the diagnostic threshold for panic disorder 1.

Roughly 4.7% of U.S. adults will develop panic disorder during their lifetime, according to the National Comorbidity Survey Replication 2. Women are diagnosed at twice the rate of men. The median age of onset is 24, though drug-induced panic episodes can begin at any age. Because panic attacks mimic cardiac emergencies, about 25% of patients presenting to emergency departments with chest pain meet criteria for panic disorder after cardiac workup is negative 3.

Drugs That Can Trigger Panic Attacks

Certain medications and substances lower the threshold for panic through sympathomimetic, serotonergic, or GABAergic mechanisms. Recognizing these triggers prevents misdiagnosis and unnecessary escalation of psychiatric medication.

Stimulants and sympathomimetics. Amphetamine-based ADHD medications (mixed amphetamine salts, lisdexamfetamine) and methylphenidate increase norepinephrine release in the locus coeruleus, a brainstem nucleus implicated in the panic response. Caffeine at doses above 400 mg per day can provoke panic in susceptible individuals, and a controlled study in patients with panic disorder found that caffeine 480 mg induced panic attacks in 61% of subjects versus 12% on placebo 4.

Cannabis and THC. High-THC cannabis strains activate CB1 receptors in the amygdala. A 2020 meta-analysis of 12 observational studies reported a pooled odds ratio of 1.9 (95% CI 1.4 to 2.5) for panic attacks among regular cannabis users compared with non-users 5.

Corticosteroids. Prednisone and dexamethasone at supraphysiologic doses disrupt HPA axis feedback and can produce anxiety, agitation, and panic. Psychiatric symptoms occur in an estimated 5% to 18% of patients receiving high-dose systemic corticosteroids 6.

Fluoroquinolone antibiotics. The FDA added a boxed warning in 2016 noting that fluoroquinolones (ciprofloxacin, levofloxacin) are associated with CNS effects including anxiety and panic 7.

Thyroid hormone excess. Iatrogenic hyperthyroidism from levothyroxine over-replacement mimics panic through beta-adrenergic overstimulation. TSH should be checked in any patient presenting with new-onset panic symptoms while on thyroid hormone 8.

Other reported triggers include decongestants containing pseudoephedrine, albuterol inhalers at high doses, and abrupt withdrawal from benzodiazepines, alcohol, or barbiturates.

SSRIs: The First-Line Pharmacotherapy

Selective serotonin reuptake inhibitors are the foundation of panic disorder treatment. Three SSRIs have FDA-approved indications for panic disorder: paroxetine, sertraline, and fluoxetine.

Paroxetine was the first SSRI approved for panic disorder. A key 10-week trial (N=278) demonstrated that paroxetine 40 mg/day reduced panic attack frequency by 86% from baseline, compared with 50% for placebo 9. Sertraline showed similar efficacy in a 12-week randomized controlled trial (N=176), where 62% of patients on sertraline versus 46% on placebo achieved zero panic attacks by endpoint 10.

The American Psychiatric Association (APA) Practice Guidelines state: "SSRIs are the preferred initial pharmacotherapy for panic disorder because of their favorable side-effect profile, safety in overdose, and broad efficacy across comorbid conditions" 1.

Starting doses should be low. Sertraline is typically initiated at 25 mg daily for the first week, then increased to 50 mg, with a target range of 50 to 200 mg. Paroxetine begins at 10 mg and titrates to 20 to 60 mg. This "start low, go slow" approach matters because SSRIs can transiently worsen anxiety during the first 1 to 2 weeks of treatment, a phenomenon called jitteriness syndrome 11.

Venlafaxine and SNRIs as an Alternative

Venlafaxine extended-release (Effexor XR) holds an FDA indication for panic disorder and is recommended by APA guidelines as a first-line alternative when SSRIs are not tolerated. A pooled analysis of four 12-week trials (total N=1,839) showed that venlafaxine XR 75 to 225 mg/day produced panic-free rates of 54% to 61%, compared with 35% to 48% for placebo 12.

Dr. Mark Pollack, former director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, noted: "Venlafaxine offers a reasonable alternative for patients who do not respond to or cannot tolerate SSRIs, and its dual mechanism may provide additional benefit for patients with comorbid depression" 12.

Duloxetine, another SNRI, lacks a formal panic disorder indication but is sometimes used off-label. Blood pressure monitoring is recommended with all SNRIs, as norepinephrine reuptake inhibition can produce dose-dependent hypertension in approximately 3% to 7% of patients at higher doses.

Benzodiazepines: Rapid but Risky

Benzodiazepines act on GABA-A receptors to produce anxiolysis within 15 to 30 minutes. That speed makes them useful during acute panic crises but poor choices for long-term monotherapy.

Alprazolam and clonazepam are the most prescribed benzodiazepines for panic disorder. A landmark multicenter trial (the Cross-National Collaborative Panic Study) randomized 1,168 patients to alprazolam or placebo across 14 sites and found that 55% of alprazolam-treated patients were panic-free at 8 weeks versus 32% on placebo 13. Clonazepam, with its longer half-life (18 to 50 hours versus 6 to 12 hours for alprazolam), allows twice-daily dosing and produces less interdose rebound anxiety 14.

The risks are real. Physical dependence develops in most patients within 4 to 8 weeks of continuous use. The APA guidelines recommend limiting benzodiazepine use to the first 4 to 6 weeks of SSRI initiation (as a "bridge") and then tapering gradually 1. Abrupt discontinuation after chronic use can itself provoke severe rebound panic, seizures, and a protracted withdrawal syndrome.

Current prescribing trends reflect these concerns. CDC data from 2023 showed that benzodiazepine prescribing rates declined 26% between 2015 and 2022 among adults aged 18 to 64 15.

Other Pharmacologic Options

Several second-line and adjunctive medications expand the toolkit for treatment-resistant panic disorder.

Tricyclic antidepressants. Imipramine was the first medication shown effective for panic disorder in the 1960s, and it remains an option for refractory cases. A Cochrane systematic review of 18 trials confirmed that TCAs are as effective as SSRIs for panic, though anticholinergic side effects and cardiac toxicity in overdose limit their use 16.

Buspirone. This 5-HT1A partial agonist is FDA-approved for generalized anxiety disorder but has shown inconsistent results in panic disorder trials. It is sometimes combined with an SSRI for residual anticipatory anxiety.

Mirtazapine. A small randomized trial (N=29) found mirtazapine 30 mg/day comparable to fluoxetine 20 mg for panic attack frequency reduction over 8 weeks 17. Its sedating properties can benefit patients with prominent insomnia.

Gabapentin and pregabalin. Pregabalin, approved for generalized anxiety disorder in Europe but not the U.S., has limited evidence in panic disorder specifically. A 2022 systematic review identified only three small trials, none adequately powered to draw firm conclusions 18.

MAO inhibitors. Phenelzine has demonstrated efficacy equal to imipramine in comparative trials, but dietary restrictions and drug interaction risks make it a last-resort option.

How Long Should Medication Continue

Premature discontinuation is the most common cause of panic disorder relapse. The evidence supports at least 12 to 18 months of pharmacotherapy after achieving remission.

A relapse prevention study randomized 181 SSRI responders to continuation or placebo switch and found relapse rates of 14% with continued SSRI versus 37% with placebo over 6 months 19. The Endocrine Society and APA guidelines both recommend a slow, supervised taper over 2 to 4 months rather than abrupt cessation, reducing the dose by roughly 10% to 25% every 2 weeks 1.

Patients with three or more lifetime episodes or significant comorbid agoraphobia may benefit from indefinite maintenance therapy. The decision to taper should be a shared one between clinician and patient, considering severity history, functional impairment, and patient preference.

Combining Medication with Cognitive Behavioral Therapy

Medication alone helps most patients, but the combination of pharmacotherapy with CBT produces the strongest and most durable outcomes.

A meta-analysis published in JAMA Psychiatry (42 RCTs, N=4,206) found that combined CBT plus pharmacotherapy yielded a response rate of 73%, compared with 60% for pharmacotherapy alone and 55% for CBT alone at acute treatment endpoint 20. At 6-month follow-up after treatment discontinuation, patients who had received combination treatment maintained lower relapse rates than either monotherapy group.

CBT for panic disorder typically involves 12 to 16 sessions focused on interoceptive exposure (deliberately inducing feared body sensations like elevated heart rate), cognitive restructuring of catastrophic misinterpretations, and gradual in-vivo exposure to avoided situations. The National Institute for Health and Care Excellence (NICE) guideline CG113 recommends CBT as a first-line treatment alongside or before pharmacotherapy 21.

For patients who prefer digital-first approaches, internet-delivered CBT (iCBT) programs have demonstrated non-inferiority to face-to-face CBT in a Swedish randomized trial (N=113), with a between-group effect size of d=0.02 at 10-week endpoint 22.

When to Seek Emergency Evaluation

Not every panic attack warrants an ER visit, but the first one usually does. Chest pain, shortness of breath, and tingling in patients without a prior panic diagnosis require cardiac workup to rule out acute coronary syndrome, pulmonary embolism, and arrhythmia. Once a thorough medical evaluation has excluded dangerous causes, future attacks can often be managed with a pre-established action plan: controlled breathing, PRN benzodiazepine if prescribed, and contact with a treating clinician within 24 to 48 hours if attack frequency increases.

Patients taking medications known to provoke panic (stimulants, high-dose corticosteroids, fluoroquinolones) should inform both their prescribing physician and their psychiatrist. Dose adjustment or drug substitution resolves many drug-induced cases without adding a psychiatric medication. Abrupt discontinuation of a suspected trigger drug should only occur under medical supervision, particularly with corticosteroids or benzodiazepines where tapering is mandatory.

The most current APA guideline recommendation for newly diagnosed panic disorder: start an SSRI at low dose, offer CBT referral at the same visit, and schedule follow-up at 2 weeks and again at 6 weeks to assess early response and adjust dosing 1.